Abstract Library

#2709 Endoscopic Management and Outcomes of Gastro-Duodenal Neuroendocrine Tumours

Introduction: Gastric and duodenal neuroendocrine tumours are increasing in incidence. ENETS guidelines suggest endoscopic resection of type 1 gastric NENs over 10mm and consider endoscopic resection for duodenal NENs. However, the endoscopic techniques are not clearly mandated. There, is evidence to suggest endoscopic mucosal dissection has higher incidence of R0 resections compared with polypectomy or EMR alone.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Victor A

Authors: Victor A, Pizanias M, Gulati S, Gunasingham N, Ramage J,

Keywords: EMR, ESD, gastric NENS, duodenal NENS,

#2077 Linked Colour Imaging Increases the Diagnostic Yield of Type 1 Gastric Carcinoids

Introduction: Type 1 Gastric carcinoid tumours (GCTs) are the most common neuroendocrine tumours of the stomach. Endoscopic diagnosis of Type 1 GCTs remains a challenge. White light endoscopy (WLE) and Narrow Band Imaging (NBI) have failed to demonstrate reliable endoscopic signs of carcinoid.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Gulati S

Authors: Gulati S, Sriraja R, Ramage J, Emmanuel A, Haji A,

Keywords: gastric carcinoid, gastric neuroendocrine tumors, endoscopy, therapy, surveillance, polypectomy, endoscopic resection,

#927 Laparoscopic Antrectomy: A Safe and Definitive Treatment in Managing Type 1 Gastric Carcinoids

Introduction: Various type 1 gastric carcinoid (T1GC) treatments exist, including esophagastroduodenoscopy (EGD) observation, polypectomy, and antrectomy, but studies comparing treatment outcomes have been limited.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Jenny H, Fujitani K, Rustagi S, Warner R, Divino C,

Keywords: antrectomy, gastric carcinoid,

#406 YF476, a Gastrin Receptor Antagonist, Causes Regression of Tumors and Normalizes Serum Chromogranin A in Patients with Type 1 Gastric Carcinoids

Introduction: Chronic atrophic gastritis (CAG) results in achlorhydria, hypergastrinemia and, in some patients, gastric carcinoids (type 1 GCs). Type 1 GCs may become malignant and metastasize. Current treatments of type 1 GCs, such as polypectomy, somatostatin analogues and antrectomy, have their disadvantages. YF476 – a potent, selective, orally active and well-tolerated gastrin receptor antagonist in pre-clinical studies – prevented, as well as reduced, the number and size of gastric carcinoids and carcinomas in rodent models.

Conference: 9th Annual ENETSConcerence (2012)

Presenting Author:

Authors: Fossmark R, Sørdal �, Jianu C, Qvigstad G, Boyce M,

Keywords: gastric carcinoids, gastrin, chromogranin A,